Featured Research

from universities, journals, and other organizations

Improved adherence to preventive antiretroviral therapy may reduce transmission of HIV

September 10, 2013
Massachusetts General Hospital
A recently completed study found that pre-exposure prophylaxis -- a new strategy to prevent HIV infection by prescribing a daily antiretroviral drug to at-risk individuals -- can be a powerful tool when participants take their medications.

A recently completed substudy of a larger clinical trial found that pre-exposure prophylaxis -- a new strategy to prevent HIV infection by prescribing a daily antiretroviral drug to at-risk individuals -- can be a powerful tool when participants take their medications. The trial of this strategy, also called PrEP, enrolled uninfected individuals in East Africa with an HIV-positive sexual partner and found that a combination of objective monitoring of how often participants took their daily medications and intensive counseling of those with lower rates of adherence prevented any HIV infection among those receiving active medication during an average follow-up period of nearly one year.

Related Articles

"Our study shows that PrEP can be extremely effective in preventing HIV infection when adherence to daily dosing is high," says Jessica Haberer, MD, MS, of the Center for Global Health at Massachusetts General Hospital (MGH), lead author of the article in the September 10 issue of PLOS Medicine. "Previous studies of PrEP have found considerable variance in efficacy, ranging from as high as 75 percent to no effect at all. We think that the different levels of adherence in those trials explain the differences in their findings, a hypothesis that is supported by this new study."

The larger Partners PrEP Study was conducted from July 2008 until July 2011 at nine clinical sites in Kenya and Uganda and enrolled almost 5,000 couples, one member of which was HIV-infected and the other was not. Uninfected participants were prescribed daily oral medications -- either one of two different antiretroviral formulations or a placebo. At the outset of the trial and at monthly intervals during the study period, both members of the couples received counseling on the importance of following the trial protocol, including consistently taking the study drug, and other ways to prevent HIV transmission.

Since early experience in PrEP trials indicated that limited adherence might be a significant problem, the Partners PrEP team added a substudy focused on improving adherence. Preliminary results of the overall Partners PrEP Study were so strong, showing a 62 to 75 percent reduction in the incidence of infection, that it was stopped early, so the adherence component was applied only to a subgroup of almost 1,150 couples enrolled at three sites in Uganda. The earlier clinical trials of PrEP that included any measures of adherence relied on things like participants' reports of how many pills they had taken and pill counts or blood tests on the day of scheduled clinic visits. Such measures may be unreliable, as participants can misreport how well they followed a protocol, dump out extra unused pills or take medications only on the days before a scheduled visit.

The adherence substudy adopted two objective measures known to reflect more accurately how well participants follow a study protocol -- unannounced in-home visits to count the pill supply and an automated microchip-based system that records each time the pill bottle is opened. Participants whose pill-count-measured adherence for a three-month period dropped below 80 percent received more intense counseling, with additional information on the importance of adherence and help with strategies to identify and overcome factors that reduced adherence. The HIV-infected partners were also included in these counseling sessions, if they chose, and participants could schedule as many sessions as they felt would be helpful.

At the end of the clinical trial, only 14 of the 1,147 uninfected participants in the adherence substudy had contracted HIV, all of whom had been in the placebo group -- a finding that equates to 100 percent efficacy of PrEP. Average adherence rates over the whole trial were 99 percent, measured by unannounced pill count, and 97 percent, measured by the automated monitoring system. Among participants who were assigned the adherence intervention early enough in the study period to have subsequent pill counts, 92 percent had a greater than 80 percent adherence at the next count, and 82 percent maintained that level for the rest of the study period.

"This study suggests that PrEP is highly effective when taken," says study senior author David Bangsberg, MD, PhD, director of the MGH Center for Global Health and a professor of Medicine at Harvard Medical School (HMS). "We believe that studying participants in committed relationships, where both partners are supporting adherence, was part of the reason that participants in this study experienced such a high degree of protection."

The researchers also found that adherence to the study protocol was most strongly influenced by relationship factors. Participants who reported having no sexual activity during the previous three months were more likely to report not having taken their pills -- probably because they felt they were not at risk of infection -- as were those who reported having more than one sexual partner or not consistently using condoms. In contrast, participants in stable polygamous marriages, which are culturally accepted in the parts of Africa where the study was conducted, were more likely to closely follow the study protocol. Other factors associated with less adherence were youth and heavy alcohol use. Adherence also decreased over time, possibly reflecting a drop-off in motivation during the study period.

"PrEP is another important biomedical tool for the prevention of HIV infection in sub-Saharan Africa or anywhere in the world where people are at high risk for acquiring the virus," says Haberer, an assistant professor of Medicine at HMS. "No one tool will work for all people in all settings, so it's important to have options. PrEP may make sense for couples like those in this study, particularly if they want to have children -- in which case they would not be using condoms or abstaining from sex -- but not for individuals who have trouble taking pills on a daily basis. It also may be a good option for couples in which the HIV-infected individual doesn't qualify for antiretroviral therapy, which was the case for most couples in this study."

Haberer is now collaborating on the PrEP Demonstration Project in East Africa, which includes comprehensive counseling on treatment safety, efficacy and the importance of adherence -- without the intensive adherence intervention -- and should more accurately replicate "real world" clinical treatment. "We think that this project and others like it will be highly informative of how well people can take PrEP outside the structured settings of clinical trials," she says. "The data on the acceptability and efficacy of PrEP that these projects will yield should help public officials make difficult decisions about where to spend their limited funds for HIV prevention."

Story Source:

The above story is based on materials provided by Massachusetts General Hospital. Note: Materials may be edited for content and length.

Journal Reference:

  1. Jessica E. Haberer, Jared M. Baeten, James Campbell, Jonathan Wangisi, Elly Katabira, Allan Ronald, Elioda Tumwesigye, Christina Psaros, Steven A. Safren, Norma C. Ware, Katherine K. Thomas, Deborah Donnell, Meighan Krows, Lara Kidoguchi, Connie Celum, David R. Bangsberg. Adherence to Antiretroviral Prophylaxis for HIV Prevention: A Substudy Cohort within a Clinical Trial of Serodiscordant Couples in East Africa. PLOS Medicine, September 2013

Cite This Page:

Massachusetts General Hospital. "Improved adherence to preventive antiretroviral therapy may reduce transmission of HIV." ScienceDaily. ScienceDaily, 10 September 2013. <www.sciencedaily.com/releases/2013/09/130910205439.htm>.
Massachusetts General Hospital. (2013, September 10). Improved adherence to preventive antiretroviral therapy may reduce transmission of HIV. ScienceDaily. Retrieved January 25, 2015 from www.sciencedaily.com/releases/2013/09/130910205439.htm
Massachusetts General Hospital. "Improved adherence to preventive antiretroviral therapy may reduce transmission of HIV." ScienceDaily. www.sciencedaily.com/releases/2013/09/130910205439.htm (accessed January 25, 2015).

Share This

More From ScienceDaily

More Health & Medicine News

Sunday, January 25, 2015

Featured Research

from universities, journals, and other organizations

Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Mistakes Should Serve a Lesson Says WHO

Ebola Mistakes Should Serve a Lesson Says WHO

AFP (Jan. 25, 2015) The World Health Organization&apos;s chief on Sunday admitted the UN agency had been caught napping on Ebola, saying it should serve a lesson to avoid similar mistakes in future. Duration: 00:55 Video provided by AFP
Powered by NewsLook.com
Disneyland Measles Outbreak Spreads To 5 States

Disneyland Measles Outbreak Spreads To 5 States

Newsy (Jan. 24, 2015) Much of the Disneyland measles outbreak is being blamed on the anti-vaccination movement. The CDC encourages just about everyone get immunized. Video provided by Newsy
Powered by NewsLook.com
Growing Measles Outbreak Worries Calif. Parents

Growing Measles Outbreak Worries Calif. Parents

AP (Jan. 23, 2015) Public health officials are rushing to contain a measles outbreak that has sickened 70 people across 6 states and Mexico. The AP&apos;s Raquel Maria Dillon has more. (Jan. 23) Video provided by AP
Powered by NewsLook.com
Smart Wristband to Shock Away Bad Habits

Smart Wristband to Shock Away Bad Habits

Reuters - Innovations Video Online (Jan. 23, 2015) A Boston start-up is developing a wristband they say will help users break bad habits by jolting them with an electric shock. Ben Gruber reports. Video provided by Reuters
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.


Breaking News:

Strange & Offbeat Stories

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News


Free Subscriptions

Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile

Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?

Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins